Results 11 to 20 of about 268 (75)

Risk management of metabolic disorders in the use of antipsychotics [PDF]

open access: yesОбозрение психиатрии и медицинской психологии имени В.М. Бехтерева, 2018
Cardio-metabolic risk factors and diabetes mellitus type 2 are highly prevalent in patients with schizophrenia. Decrease of metabolic risks associated with use of atypical antipsychotics is connected with the development of specialised programs. They can
G. E. Mazo, A. O. Kibitov
doaj   +2 more sources

Is the «equivalent chlorpromazine» dose in psychopharmacotherapy consistent with Good Clinical Practice? [PDF]

open access: yesОбозрение психиатрии и медицинской психологии имени В.М. Бехтерева, 2018
Principles of adequate pharmacotherapy in psychiatry imply that shifting from one antipsychotic to another requires recalculation of the effective dose using the «chlorpromazine equivalent».
M. Yu. Popov, P. V. Kozlovskaya
doaj   +2 more sources

Hyperprolactinemia during application of second-generation antipsychotics: the principles of prevention, diagnosis and correction [PDF]

open access: yesОбозрение психиатрии и медицинской психологии имени В.М. Бехтерева, 2018
The article presents compelling evidence of the need to draw attention of physicians to the problem of neyroleptical hyperprolactinemia. The article provides information about different prolactogen activity of antipsychotics with the release of the ...
L. N. Gorobets, G. E. Mazo
doaj   +2 more sources

Pharmacogenetics of antipsychotic-induced metabolic disturbances: state-of-the-art [PDF]

open access: yesОбозрение психиатрии и медицинской психологии имени В.М. Бехтерева, 2018
Antipsychotics are the main pharmaceutical agents in treatment of schizophrenia and other mental disorders. According to literature data up to 60% of patients with schizophrenia have antipsychotic-induced metabolic disturbances.
R. F. Nasyrova   +9 more
doaj   +2 more sources

Budget impact of modern drugs for the treatment of schizophrenia: regional aspects [PDF]

open access: yesКачественная клиническая практика, 2018
The article presents the results of comparative pharmacoeconomic analysis of treatment of schizophrenia with antipsychotics of the first and second generation in Khabarovsk territory.
K. V. Krot   +2 more
doaj   +2 more sources

Фармакоэкономический анализ эффективности затрат современных атипичных антипсихотиков у больных шизофренией [PDF]

open access: yesКачественная клиническая практика, 2018
Актуальность. Около 15% от всех больных с шизофрений трудоспособного возраста, состоящих под диспансерным наблюдением, попадают в группу пациентов с неустойчивой трудовой адаптацией.

doaj   +2 more sources

Patient social function and quality of life in schizophrenia: focus on paliperidone palmitate [PDF]

open access: yesОбозрение психиатрии и медицинской психологии имени В.М. Бехтерева, 2018
The long-term outcomes of treatment with new selective antipsychotic for patients with schizophrenia have been discussed. Using the example of patients treated with “Xeplion” for secondary prevention of worsening symptoms of the disorder and changing in ...
E. V. Grigorieva
doaj   +2 more sources

Клініко-терапевтичні особливості пацієнтів із шизотиповим розладом з обсесивно-компульсивною симптоматикою [PDF]

open access: yes, 2022
Introduction. The prevalence of obsessive-compulsive symptoms in modern conditions of high stress and the lack of detailed recommendations for this category of patients determine the relevance of this publication.
Chelyadyn, Yuliya   +1 more
core   +2 more sources

Electroconvulsive Therapy as a Corrector for Certain Side Effects of Antipsychotic Therapy [PDF]

open access: yes, 2020
The discovery of the first typical antipsychotics in the 1950s had revolutionized the treatment of many severe mental illnesses. This discovery opened the door for radical humanization and deinstitutionalization of the whole psychiatry. It also served as
R. A. Bekker, Yu. V. Bykov
core   +2 more sources

Home - About - Disclaimer - Privacy